CYBIN INC (CYBN)

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

Cybin to Participate at the 27th Annual Milken Institute Global Conference

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

3 Penny Stocks That Could Be Multibaggers in the Making: March Edition

Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while.

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003

3 High-Potential Penny Stocks to Turn $1000 into $1 million

U.S. equities are in the midst of a steady rally, but these high-potential penny stocks are likely to trounce the major indices.

Cybin to Present at the TD Cowen 44th Annual Health Care Conference

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

Psychedelic stocks gain after FDA priority review for MDMA therapy (NYSE:CYBN)

The FDA priority review for an MDMA-linked therapy leads to a surge in shares of psychedelic medicine companies such as Mind Medicine (MNMD). Read more here.

Cybin reports Japan grant of additional patents for anxiety disorder treatment (NYSE:CYBN)

Cybin Inc. receives two patents from the Japan Patent Office for its anxiety disorder treatment, offering protection for synthesis methods and injectable...

Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition

/PRNewswire/ -- The coming years could see a massive shift in the U.S. government's approach to regulating hallucinogenic drugs. Several biopharma companies...

Cybin gets FDA clearance for Phase 2a study of psychedelic drug (NYSE:CYBN)

Cybin (CYBN) said it has received FDA clearance to initiate a Phase 2a study for its psychedelic drug candidate CYB004 in the treatment of anxiety. Read more here.

Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder

Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs